Every material Form 8-K Edgewell Personal Care filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Edgewell Personal Care reported fourth-quarter and fiscal 2025 results on November 13, 2025, with a fourth-quarter GAAP net loss of $30.6 million after a $51.1 million goodwill impairment tied to its Feminine Care business. Fiscal 2025 GAAP EPS was $0.53, down from $1.97, and the company gave fiscal 2026 guidance that excludes the planned $340 million sale of Feminine Care to Essity.
Q4 net sales were $537.2 million, up 3.8%, but the company posted a GAAP net loss of $30.6 million, or $0.66 per diluted share, versus net income of $8.8 million a year earlier.
Q4 included a non-cash goodwill impairment charge of $51.1 million for the Feminine Care reporting unit.
Fiscal 2025 net sales were $2,223.5 million, down 1.3%, and GAAP diluted EPS was $0.53 versus $1.97 in fiscal 2024.
Fiscal 2026 adjusted EPS is expected at $2.15 to $2.55, compared with fiscal 2025 adjusted EPS of $2.52; the outlook excludes the $340 million Feminine Care divestiture to Essity.
Edgewell Personal Care agreed on November 12, 2025 to sell its Feminine Care segment to Essity for $340 million in cash, subject to customary adjustments. The closing is expected in the first quarter of calendar 2026, pending regulatory approvals, and the company expects the sale to reduce its adjusted EPS and adjusted EBITDA on an annualized basis, net of transition service income.
Buyer: Essity Aktiebolag (publ); consideration is $340 million in cash, subject to adjustments for inventory, indebtedness and other items
Expected closing in the first quarter of calendar 2026; the outside date is May 12, 2026, with extensions to as late as November 12, 2026
Company expects an annualized impact of approximately $0.40 to $0.50 in adjusted EPS and $35 million to $45 million in adjusted EBITDA, net of transition services income
Net proceeds, after taxes and transaction costs, are intended primarily to strengthen the balance sheet; the company would receive a $15 million termination fee in certain circumstances
Edgewell Personal Care said its Chief Operating Officer, Daniel Sullivan, will resign effective October 1, 2025, to pursue another opportunity. The company will not fill the COO role and will instead use four regional hubs that report directly to the CEO, which the company says is meant to streamline operations.
Daniel J. Sullivan informed the company of his resignation on August 29, 2025; it takes effect October 1, 2025.
The COO position will not be replaced.
Four regional hubs (North America, Europe, Asia and Latin America) will report directly to CEO Rod Little, alongside the CFO and Chief Supply Chain Officer.
The company announced the change in a press release dated September 5, 2025 (Exhibit 99.1).
Edgewell Personal Care reported third-quarter fiscal 2025 net sales of $627.2 million, down 3.2%, with adjusted EPS of $0.92 versus $1.22 a year earlier. The company lowered its full-year fiscal 2025 outlook, including adjusted EPS of about $2.65 versus a prior range of $2.85 to $3.05, citing weak Sun Care seasons, tariffs and foreign exchange, which points to lower profit and cash generation for shareholders this year.
Q3 net sales were $627.2 million, down 3.2%; organic net sales fell 4.2% and North America organic sales fell 8.0%.
Q3 GAAP diluted EPS was $0.62 versus $0.98, and adjusted EPS was $0.92 versus $1.22 in the prior year quarter.
FY2025 adjusted EPS is now expected to be about $2.65 (previously $2.85 to $3.05); GAAP EPS is now about $1.73 (previously $2.09 to $2.29).
FY2025 free cash flow is now expected to be about $80 million (previously $130 million to $140 million); the board declared a $0.15 quarterly dividend payable October 8, 2025.
Edgewell Personal Care reported second-quarter fiscal 2025 net sales of $580.7 million, down 3.1% from the prior year, and GAAP diluted EPS of $0.60 versus $0.72. The company lowered its full-year fiscal 2025 outlook, including GAAP EPS of $2.09 to $2.29 (previously $2.54 to $2.74) and free cash flow of $130 million to $140 million (previously $185 million), which weighs on shareholder returns.
Q2 net sales $580.7 million, down 3.1%; organic net sales down 1.5%
GAAP diluted EPS $0.60 vs $0.72 a year earlier; adjusted EPS $0.87 vs $0.88
Full-year adjusted EPS now $2.85 to $3.05, versus previously towards the lower end of $3.15 to $3.35
Full-year free cash flow now $130 million to $140 million, down from $185 million; six-month operating cash flow was negative $70.5 million
Edgewell reported first-quarter fiscal 2025 net sales of $478.4 million, down 2.1%, and a GAAP loss of $0.04 per diluted share, versus earnings of $0.09 a year earlier. The company lowered its full-year GAAP EPS outlook to $2.54 to $2.74 from $2.59 to $2.79, citing foreign currency changes, and said adjusted EPS will be toward the lower end of its $3.15 to $3.35 range. Shareholders also voted at the February 6, 2025 annual meeting, re-electing all ten director nominees and approving the auditor and executive pay proposals.
Net sales were $478.4 million versus $488.9 million a year earlier; organic net sales decreased 1.3%.
GAAP diluted EPS was $(0.04) versus $0.09; adjusted EPS was $0.07 versus $0.24, including a $0.17 unfavorable currency impact.
Full-year fiscal 2025 GAAP EPS outlook was lowered to $2.54 to $2.74 from $2.59 to $2.79; adjusted EPS is now expected toward the lower end of $3.15 to $3.35.
At the February 6, 2025 annual meeting, all ten director nominees were elected and PricewaterhouseCoopers LLP was ratified as auditor.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Edgewell Personal Care filing is on SEC EDGAR ↗. 8-K briefs of other companies →